

CITATION REPORT

List of articles citing

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

DOI: 10.1111/dom.12670

Diabetes, Obesity and Metabolism, 2016, 18, 783-94.

Source: <https://exaly.com/paper-pdf/65039788/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
304	Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. 2016 , 2016, 5347262		17
303	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. 2016 , 11, e0166125		126
302	The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. 2016 , 2016, 144-6		22
301	Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. 2016 , 19, 1175-1186		27
300	I nuovi farmaci per il diabete: gli inibitori del co-trasportatore sodio-glucosio di tipo 2 (SGLT-2i). 2016 , 17, 259-261		
299	Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. 2016 , 121, 204-214		33
298	SGLT2 Inhibitors: Benefit/Risk Balance. 2016 , 16, 92		64
297	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. 2016 , 15, 95		39
296	DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. 2016 , 12, 1407-1417		57
295	Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data. 2016 , 147 Suppl 1, 44-48		1
294	Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. 2017 , 40, 535-540		24
293	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. 2017 , 19, 7		36
292	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. 2017 , 11, 450-458.e1		21
291	WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. 2017 ,		
290	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. 2017 , 18, 517-527		4
289	Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. 2017 , 33, 1317-1328		15
288	Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1655-1668	6.7	55

287	Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks. 2017 , 102, 470-480		2
286	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. 2017 , 71, e12948		14
285	Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. 2017 , 33, 1155-1163		4
284	Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. 2017 , 13, 583-592		7
283	Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. 2017 , 10, 633-647		1
282	SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. 2017 , 23, 831-840		9
281	Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. 2017 , 56, 703-718		28
280	Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 524-536	6.7	216
279	The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. 2017 , 41, 517-523		9
278	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. 2017 , 10, 1303-1316		4
277	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. 2017 , 17, 112		18
276	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. 2017 , 8, 1175-1185		3
275	The effect of SGLT2 inhibitors on cardiovascular events and renal function. 2017 , 10, 1251-1261		9
274	Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. 2017 , 27, 1098-1107		21
273	Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. 2017 , 27, 1108-1113		47
272	Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. 2017 , 7, 2824		100
271	Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. 2017 , 129, 686-697		32
270	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. 2017 , 16, 42		49

269	Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 348-355	6.7	106
268	Non-insulin anti-diabetic drugs: An update on pharmacological interactions. 2017 , 115, 14-24		15
267	The Na-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. 2017 , 170, 148-165		65
266	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. 2017 , 13, 399-408		15
265	Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 49-60	6.7	52
264	Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 142-147	6.7	39
263	A Case of Septic Shock Due to <i>Serratia marcescens</i> Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin. 2017 , 30, 672-675		7
262	Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. 2017 , 32, 974-983		16
261	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. 2017 , 12, 1-10		5
260	Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. 2017 , 41, 357-366		17
259	SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. 2018 , 55, 503-514		91
258	Is the management of diabetes different in dialysis patients?. 2018 , 31, 367-376		5
257	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis. 2018 , 140, 295-303		15
256	Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. 2018 , 35, 1037-1048		29
255	Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. 2018 , 9, 565-581		10
254	Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study. 2018 , 9, 403-411		6
253	Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. 2018 , 137, 83-92		27
252	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. 2018 , 360, k119		93

251	Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. 2018 , 61, 1592-1602		18
250	A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. 2018 , 34, 1143-1152		7
249	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. 2018 , 18, 27		36
248	Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies. 2018 , 29, 246-258		5
247	SGLT2 inhibitors: are they safe?. 2018 , 130, 72-82		36
246	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 620-628	6.7	89
245	Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 458-462	6.7	145
244	Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 520-529	6.7	101
243	An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin. 2018 , 9, 125-140		
242	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. 2018 , 47, 97-116		2
241	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. 2018 , 9, CD011798		27
240	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. 2018 , 14, 1287-1302		41
239	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. 2018 , 8, e023206		4
238	Antihyperglycemic and Antilipidemic Effects of the Ethanol Extract Mixture of and in Type II Diabetes-Mimicking Mice. 2018 , 2018, 3468040		3
237	Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. 2018 , 6, E594-E602		17
236	Physical exercise and non-insulin glucose-lowering therapies in the management of Type 2 diabetes mellitus: a clinical review. 2019 , 36, 349-358		8
235	HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING. 2018 , 24, 273-287		10
234	12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. 2018 , 10, 141-151		12

233	Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis. 2018 , 2018, 6450563		10
232	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018 , 30, 137-153		8
231	Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. 2018 , 44, 373-375		2
230	Empagliflozin: A Review in Type 2 Diabetes. 2018 , 78, 1037-1048		40
229	Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2919-2924 ^{6.7}		5
228	A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2876-2884	6.7	19
227	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2711-2723	6.7	16
226	The European Medicines Agency's approval of new medicines for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2059-2063	6.7	12
225	Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. 2018 , 9, 1945-1958		13
224	The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. 2018 , 61, 2098-2107		125
223	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018 , 30, 137-153		1
222	Increase in glycated haemoglobin concentrations after unwarranted prescription changes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2510-2511	6.7	1
221	Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes. 2018 , 8, 8805		17
220	Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. 2019 , 39, 122-127		1
219	Dyslipidemia in Diabetes. 2019 , 186-198		2
218	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease. 2019 , 75, 1481-1490		5
217	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. 2019 , 16,		76
216	Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. 2019 , 18, 107		44

215	Sodium-Glucose Cotransporter 2 Inhibitors. 2019 , 531-539	
214	Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects. 2019 , 20, 74	0
213	Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoconomics evaluation. 2019 , 157, 107867	
212	Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling. 2019 , 18, 143	14
211	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. 2019 , 132, S49-S57.e5	7
210	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. 2019 , 12, 2125-2136	26
209	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. 2019 , 15, 519-530	0
208	Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. 2021 , 17, 451-462	4
207	The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. 2019 , 10, 1771-1792	27
206	Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. 2019 , 18, 120	26
205	Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. 2019 , 10, 473-491	13
204	Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis. 2019 , 41, 322-334.e11	16
203	Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. 2018 , 9, 1517	25
202	Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. 2019 , 10, 393-428	10
201	Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. 2019 , 79, 219-230	82
200	SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. 2019 , 55,	21
199	Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. 2019 , 21, 70	41
198	Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. 2019 , 98, 27-36	13

197	Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. 2019 , 8, 889-905		4
196	Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. 2019 , 8, 380-395		15
195	What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 43-52	6.7	33
194	Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. 2019 , 16, 415-423		18
193	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 9-18	6.7	43
192	Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. 2019 , 10, 480		8
191	Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. 2019 , 18, 59		11
190	Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. 2019 , 39, 521-531		13
189	Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm. 2019 , 13, 1935-1942		4
188	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. 2019 , 20, 781-790		4
187	Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1474-1482	6.7	27
186	Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. 2019 , 9, e022577		89
185	Metabolism of the failing heart and the impact of SGLT2 inhibitors. 2019 , 15, 275-285		32
184	Risk assessment of urinary tract infections for patients receiving dapagliflozin. 2019 , 36, 1041-1048		
183	Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i). 2019 , 35, 1607-1614		3
182	Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. 2019 , 151, 65-73		15
181	Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney. 2019 , 34, 2015-2017		5
180	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. 2019 , 7, e000725		19

179	Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. 2019 , 7, e000704	5
178	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. 2019 , 124 Suppl 1, S45-S52	30
177	Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. 2019 , 9, 19351	27
176	Efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type II diabetes: A protocol for systematic review of randomised controlled clinical trials utilising a generalised pairwise modelling methodology. 2019 , 98, e18198	
175	Fighting Type-2 Diabetes: Present and Future Perspectives. 2019 , 26, 1891-1907	10
174	Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 434-438	6.7 41
173	New pharmacological strategies for protecting kidney function in type 2 diabetes. 2019 , 7, 397-412	44
172	Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. 2019 , 131, 31-42	42
171	A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. 2019 , 105, 1213-1223	39
170	Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. 2019 , 36, 444-452	20
169	Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. 2019 , 148, 222-233	1
168	Common Questions and Misconceptions in the Management of Renal Transplant Patients: A Guide for Health Care Providers in the Posttransplant Setting. 2019 , 53, 419-429	1
167	Proinsulin C-peptide as an alternative or combined treatment with insulin for management of testicular dysfunction and fertility impairments in streptozotocin-induced type 1 diabetic male rats. 2019 , 234, 9351-9357	3
166	Medications for the Treatment of Type II Diabetes. 2019 , 101-106	
165	Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. 2019 , 85, 160-168	17
164	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. 2019 , 70, 323-334	18
163	Update on postprandial hyperglycaemia: the pathophysiology, prevalence, consequences and implications of treating diabetes. 2020 , 220, 57-68	1
162	Update on postprandial hyperglycemia: The pathophysiology, prevalence, consequences and implications of treating diabetes. 2020 , 220, 57-68	1

161	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. 2020 , 104, 154045		12
160	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. 2020 , 38, 377-386		3
159	Obesity medications in development. 2020 , 29, 63-71		14
158	Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes. 2020 , 132, 697-701		1
157	Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. 2020 , 23, 842-850		3
156	Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance. 2020 , 54, 11-17		5
155	SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging. 2020 , 8,		6
154	Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. 2020 , 9,		2
153	Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. 2020 , 63, 2129-2139		6
152	Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. 2020 , 99, e20735		1
151	Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2384-2397	6.7	2
150	Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2276-2286	6.7	4
149	SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. 2020 , 12, 1961-1990		7
148	Inhibidores de la SGLT2. ¿Cuáles el lugar en terapéutica?. 2020 , 27, 419-427		
147	Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. 2020 , 43, 1211-1221		12
146	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. 2020 , 142, 1205-1218		16
145	The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1 β signalling pathway. 2020 , 9, 484-494		32
144	Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. 2020 , 16, 556-577		67

143	Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes. 2020 , 63, 1424-1434		8
142	Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. 2020 , 11, 1347-1367		10
141	Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1722-1728	6.7	4
140	Cardiovascular outcome trials of glucose-lowering therapies. 2020 , 20, 237-249		4
139	Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?. 2020 , 9,		5
138	Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. 2020 , 19, 87		15
137	Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. 2020 , 11, 245-251		7
136	Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus. 2020 , 28, 724-732		5
135	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. 2020 , 160, 105052		6
134	The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers. 2020 , 13, 215-225		3
133	Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1035-1046	6.7	26
132	Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED). 2020 , 4, bvz017		19
131	A Recent Achievement In the Discovery and Development of Novel Targets for the Treatment of Type-2 Diabetes Mellitus. 2020 , 12, 1-15		21
130	The Place of Sulfonylureas in Guidelines: Why Are There Differences?. 2020 , 11, 5-14		8
129	Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. 2021 , 17, 65-77		29
128	Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis. 2021 , 172, 108562		2
127	Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. 2021 , 38, 594-606		1
126	Clinical Outcomes, Trends in Weight, and Weight Loss Strategies in Patients With Obesity After Durable Ventricular Assist Device Implantation. 2021 , 18, 52-63		4

125	The facile synthesis of a CoO-NiNP composite as an electrochemical non-enzymatic sensing platform for small chemical molecules. 2021 , 13, 2229-2237	1
124	Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. 2021 , 12, 2042098621989134	14
123	Clonal diversity of the B cell receptor repertoire in patients with coronary in-stent restenosis and type 2 diabetes. 2021 , 16, 884-898	1
122	SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. 2021 , 20, 39	6
121	Role of SGLT2 inhibitors in the treatment of visceral obesity. 2021 , 20, 2648	
120	Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2. 2021 , 10,	1
119	SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. 2021 , 1	10
118	Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD. 2021 , 43, 320-335	6
117	Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. 2021 , 178, 1756-1771	5
116	Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports. 2021 , 21, 284	1
115	Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. 2021 , 12, 1279-1297	4
114	Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data. 2021 , 30, 644-651	4
113	SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. 2021 , 22,	4
112	Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?. 2021 , 2, 1174-1178	4
111	Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. 2021 , 46, 101158	3
110	Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes. 1-30	
109	Promising areas of pharmacotherapy for obesity. 2021 , 26, 4279	2
108	Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. 2021 , 331, 243-248	3

107	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients. 2021 , 11, 10166	5
106	Hypertension: Current trends and future perspectives. 2021 , 87, 3721-3736	2
105	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. 2021 , 22,	16
104	Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?. 2021 , 114, 351-358	
103	Canagliflozin: metabolic, cardiovascular and renal protection. 2021 , 17, 443-458	3
102	Clinical outcomes of Sodium-glucose cotransporter-2 inhibitors in patients with Type 2 Diabetes Mellitus: An observational study from Pakistan. 2021 , 37, 1342-1346	0
101	A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment. 2021 , 274, 119069	2
100	Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. 2021 , 10,	1
99	An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. 2021 , 22, 2087-2094	1
98	An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: A VigiBase study. 2021 , 30, 1428-1440	1
97	An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). 2021 , 14, 2955-2972	1
96	Anti-Inflammatory Effect of Nephroprotective Therapy in Patients with Diabetic Nephropathy. 2021 , 6, 192-198	
95	Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland. 2021 , 22,	10
94	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. 2021 , 12, 708372	2
93	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. 2021 , 23, 1260-1275	12
92	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study. 2021 ,	3
91	Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. 2021 ,	
90	Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). 2021 , 66, 1571-1580	5

89	Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). 2021 , 66, 1581-1590		6
88	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. 2021 , 330, 8-13		1
87	Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis. 2021 ,		
86	Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study. 2021 , 1		4
85	A possible follow-up method for diabetic heart failure patients. 2021 , 75, e14794		
84	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. 2021 , 4, 100102		
83	Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study. 2021 , 2, 165-175		
82	Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: A systematic review and meta-analysis of randomized clinical trials. 2021 , 180, 109033		2
81	Differential Effect of Canagliflozin, a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, on Slow and Fast Skeletal Muscles From Nondiabetic Mice.		
80	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. 2020 , 11, 33-48		10
79	[New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus]. 2019 , 36, 145-161		3
78	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. 2020 , 29, 112-118		10
77	Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 985-997	6.7	16
76	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. 2020 , 8,		14
75	Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. 2016 , 11, e0165703		94
74	Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus. 2017 , 9, 745-753		18
73	SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. 2019 , 15, 349-356		3
72	Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice. 2019 , 43, 590-606		11

71	Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement. 2017 , 21, 210-230		9
70	Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. 2021 , 41, 331-348		1
69	Energy intake and weight during the COVID-19 lockdown were not altered in a sample of older adults with type 2 diabetes in England. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	1
68	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. 2021 ,		4
67	Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia. 2018 , 100-108		
66	Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment. 2018 , 10, 381-385		
65	Drugs for Treatment of Diabetes Mellitus. 2019 , 241-251		
64	Long-term efficacy of gliflozins versus gliptins for Type 2 Diabetes after metformin failure: a systematic review and network meta-analysis. 2020 , 66, 458-465		
63	Short Term Use of Empagliflozin Does Not Improve Left Ventricular Function in Non-Diabetic Hypertensive Patients: Results from a Non-Randomised Controlled Trial. 2020 , 10, 563-571		
62	Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. 2021 , 182, 109123		1
61	[Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria]. 2020 , 92, 106-109		
60	The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients.. 2021 , 11,		1
59	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.. 2021 , 11,		2
58	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. 2021 ,		1
57	Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. 2022 , 24, 479-486		1
56	Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.. 2022 ,		0
55	Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails. 2022 , 24, 553-564		
54	SGLT2 Inhibitors and Their Antiarrhythmic Properties.. 2022 , 23,		0

53	Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.. 2022,	0
52	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.. 2022, 22, 39	5
51	Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. 2022, 2022, 1-19	1
50	Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis.. 2022, 66, 68-76	0
49	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.. 2021, 12, 785879	0
48	Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome.. 2022, 79, 593-604	0
47	Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach.. 2022, 13, 834743	0
46	Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes.. 2022,	0
45	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.. 2022, 108185	0
44	Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials.. 2022, 13, 20406223221083509	0
43	Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. 2022, 13, 20420188221090001	1
42	Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review.. 2022, 120543	2
41	Biochemical efficacy of sodium-glucose cotransporter 2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population.. 2022,	
40	Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus.. 2022,	0
39	Prescribing SGLT2 Inhibitors in Patients with Chronic Kidney Disease: Expanding Indications and Practical Considerations. 2022,	3
38	Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience. 2022, 17, 1203-1215	0
37	Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. 2022, 37, 251-259	1
36	Post-Transplant Diabetes: Prevalence, Risk, and Management Challenges. 1-14	0

35	Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes.	0
34	Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study. 2022 , 56, 152058	0
33	Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis. 1-29	
32	Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review. 9,	
31	Cardiorenal protection of SGLT2 inhibitors Perspectives from metabolic reprogramming. 2022 , 83, 104215	1
30	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. 2022 , 18, 62-72	0
29	Therapeutic peptidomimetics in metabolic diseases. 2022 , 521-550	0
28	Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach. 2022 , 94,	0
27	Risk of urinary tract infection in patients with type 2 diabetes treated with dapagliflozin: A systematic review and meta-analysis of randomized controlled studies.	0
26	Dapagliflozin for heart failure according to body mass index: the DELIVER trial.	1
25	Ethnicity and risks of severe COVID -19 outcomes associated with glucose-lowering medications: A cohort study.	0
24	Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. 2022 , 192, 110094	0
23	Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors. 2022 , 18, 529-538	0
22	Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.	0
21	Kidney-Protective Effects of SGLT2 Inhibitors. C.JN.09380822	1
20	Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials. 2022 , 16, 102657	0
19	Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.	1
18	Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. 14, 599-616	0

- 17 Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence. ○
- 16 Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study. ○
- 15 Weight-centric treatment of type 2 diabetes mellitus. **2022**, 4, 100045 ○
- 14 Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study. **2023**, 13, 21 ○
- 13 Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis. 1-10 ○
- 12 Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.. **2023**, 106667 ○
- 11 Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial. **2023**, 140, 155396 ○
- 10 SGLT2 Inhibitors: The Sweet Success for Kidneys. **2023**, 74, 369-384 ○
- 9 Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. ○
- 8 New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. **2023**, 118, 110072 ○
- 7 Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database. 14, ○
- 6 Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. ○
- 5 Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post-Authorisation Safety Study. **2023**, 14, 129-147 ○
- 4 Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?. **2023**, ○
- 3 Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. ○
- 2 The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives. **2023**, 11, 998 ○
- 1 Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2023**, 43, 209-225 ○